Coronavirus: Drugs

Department of Health and Social Care written question – answered on 5th November 2021.

Alert me about debates like this

Photo of Lord Mendelsohn Lord Mendelsohn Labour

To ask Her Majesty's Government what is the guidance for an immunosuppressed patient who has contracted COVID-19 receiving a dose of Ronapreve.

Photo of Lord Kamall Lord Kamall The Parliamentary Under-Secretary for Health and Social Care

The guidance for immunocompromised patients receiving Ronapreve, or casirivimab and imdevimab, is outlined in the Interim Clinical Commissioning Policy: Casirivimab and imdevimab for patients hospitalised due to COVID-19 which is available in an online only format. This policy states that hospitalised patients may be eligible for Ronapreve if they are:

- 12 to 49 years old and determined to be immunocompromised by multi-disciplinary team assessment, or

- 50 years old or over whether or not they are immunocompromised.

In either case, all eligible patients must also have COVID-19 infection confirmed by polymerase chain reaction test or where a multidisciplinary team has a high level of confidence that the clinical and/or radiological features suggest that COVID-19 is the most likely diagnosis, be hospitalised specifically for the management of acute symptoms and be negative for baseline serum anti-spike antibodies against COVID-19.

Immunocompromised patients will not be eligible for Ronapreve if they are children weighing less than 40 kilograms; they are children aged under 12 years old; they have known hypersensitivity reaction to the active substances or to any of the excipients of casirivimab and imdevimab listed in the Summary of Product Characteristics; or they have previously received treatment in hospital with casirivimab and imdevimab at the 2.4 gram (combined) dose or higher.

Interim Clinical Commissioning Policy (pdf, 339.2KB)

Does this answer the above question?

Yes0 people think so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.